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Summary
Objective To describe the incidence of febrile neutrope-
nia (FN) and use of pegfilgrastim in cancer patients with 
high overall risk of FN and to investigate the relationship 
between granulocyte-colony stimulating factor (G-CSF) 
guideline adherence and chemotherapy delivery in Cen-
tral and Eastern Europe (CEE) and Austria.
Methods Dose Intensity Evaluation Program and Pro-
phylaxis (DIEPP) was a multicentre, prospective, and 
observational study of adult patients with breast cancer, 
lymphoma, lung cancer, gastric cancer, and ovarian can-
cer, who received chemotherapy with pegfilgrastim sup-
port and who had an overall risk of FN ≥ 20 %. Physicians 
assessed patient risk factors and reported their reasons 
for administering pegfilgrastim.
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Results Patients were enrolled from 113 centres in 
CEE and Austria between August 2010 and July 2013, 
and data were analysed from 1072 patients. The most 
common tumour types were breast cancer (50 %) and 
lymphoma (24 %). FN incidence was 5 % overall. FN 
occurred in 3 % of patients (28/875) who received pegfil-
grastim as primary prophylaxis (PP) and 13 % of patients 
(19/142) who received it as secondary prophylaxis (SP); 
79 % of FN events in SP patients occurred in the first 
cycle before pegfilgrastim was administered. The three 
most frequently chosen reasons for using pegfilgrastim 
were planned chemotherapy with high FN risk, female 
gender, and advanced disease. Overall, 40 % of patients 
received > 90 % of their planned chemotherapy dose 
within 3 days of the planned schedule.
Conclusion FN incidence was relatively low with peg-
filgrastim PP in patients with a physician-assessed over-
all FN risk of ≥ 20 %. The most important reasons for peg-
filgrastim use were consistent with the investigators’ risk 
assessment and international guidelines.
Keywords Febrile neutropenia  · Neoplasms  · Chemo-
therapy · Granulocyte colony-stimulating factor · Obser-
vational study
Introduction
Neutropenia remains a frequent, dose-limiting toxic-
ity of cancer chemotherapy and carries the risk of life-
threatening infections, which may compromise patient 
outcomes [1–3]. Specifically, febrile neutropenia (FN) is 
considered a medical emergency with a risk of mortality 
and requiring immediate hospitalisation [1–3]. Resulting 
dose delays and dose reductions to planned chemother-
apy [4, 5] may reduce the survival of patients with poten-
tially curable malignancies [6–10].
Primary prophylaxis (PP) with pegfilgrastim, a long-
acting granulocyte-colony stimulating factor (G-CSF), 
improves patient outcomes by reducing the depth and 
duration of neutropenia, reducing infectious death 
during chemotherapy, and by helping planned chemo-
therapy dose intensity to be maintained [11–17]. The 
once-per-cycle dosing regimen of pegfilgrastim (6  mg, 
at least 24 h following chemotherapy [11]) may avoid the 
problem of suboptimal dosing of short-acting G-CSFs 
(which need to be administered as a course of daily 
injections) that has been found to occur in routine clini-
cal practice [18]. Indeed, a number of studies have shown 
pegfilgrastim to be more efficacious than short-acting 
G-CSFs [19–24].
International guidelines from the American Society 
of Clinical Oncology (ASCO), European Organization 
for Research and Treatment of Cancer (EORTC), and 
National Comprehensive Cancer Network (NCCN) are 
aligned in recommending primary G-CSF prophylaxis to 
patients at ≥ 20 % risk of FN, either arising from the che-
motherapy regimen alone, or the combination of chemo-
therapy regimen and individual FN risk factors [18, 25, 
26]. However, implementing these guidelines in routine 
clinical practice has been inconsistent [5, 27–32]. There 
are challenges in FN risk assessment because there are 
chemotherapy regimens and clinical settings in which 
FN risk assessment is unclear in the literature [33], and 
work to obtain clinical tools that indicate the contribu-
tion of individual risk factors to a patient’s overall FN risk 
is not yet complete [34, 35]. Perhaps more concerning are 
reports indicating that many patients receiving curative 
chemotherapy do not receive G-CSF PP despite physi-
cian assessment of high FN risk [5, 27–32]. Dose reduc-
tions and dose delays are common in current practice 
[5, 27–32], which may be appropriate and in accordance 
with guidelines in the palliative setting but not in the 
curative setting when maintaining chemotherapy deliv-
ery is important for survival outcomes [18, 25, 26].
A study of early breast cancer (EBC) and lymphoma 
patients in Poland, Hungary, Czech Republic, Slovakia, 
and Slovenia indicated that adherence to international 
guidelines was particularly low in these countries of 
Eastern Europe [30]. G-CSF prophylaxis was rarely used, 
and more than half of the patients had chemotherapy 
reductions or delays, resulting in suboptimal relative 
dose intensity (RDI) [30]. These results warranted further 
investigation to gain a better understanding of the char-
acteristics of patients chosen for pegfilgrastim PP and 
secondary prophylaxis (SP) and to expand the study to 
include additional tumour types and countries.
In the present study, lung, gastric, and ovarian cancer 
were chosen, in addition to lymphoma and EBC, as rep-
resentative malignant tumours that are typically treated 
with multidrug combination chemotherapy with myelo-
suppressive potential. Poland, Czech Republic, Romania, 
Slovakia, Slovenia, Hungary, and Bulgaria were selected 
as countries representative of Central and Eastern Europe 
(CEE), alongside Austria, whose health system is likely to 
be more similar to that of Western Europe [36, 37].
The aims of the current Dose Intensity Evaluation Pro-
gram and Prophylaxis (DIEPP) study were to collect infor-
mation on the frequency of FN and the use of pegfilgrastim 
in the treatment of chemotherapy-associated myelo-
suppression in patients with high overall risk of FN and 
with different cancers and to investigate the relationship 
between adherence to current guidelines and the degree of 
chemotherapy treatment compliance in CEE and Austria.
Patients and methods
Study design
DIEPP was a multicentre, prospective, and observa-
tional study. No laboratory or diagnostic tests, other than 
those performed as part of the patient’s routine care, 
were required. Patients were enrolled following admin-
istration of pegfilgrastim and were observed from the 
beginning of the first cycle of chemotherapy through the 
entire chemotherapy treatment period up to a maximum 
of eight cycles (or until the patient died, was lost to fol-
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were selected by physicians from a list of the following 
options: age ≥ 65 years; advanced stage disease/metas-
tases; planned antibiotic prophylaxis; prior FN; female; 
haemoglobin < 12  g/dl; cardiovascular disease; kidney 
disease; elevated liver enzymes; high dose intensity 
planned (≥ 80 %); bad general condition/poor nutritional 
status; one or more comorbidities; body surface area 
(BSA) < 2 m2; absolute neutrophil count (ANC) < 1.5 × 109/l 
before treatment; albumin ≤ 3.5  g/dl; lymphoma histol-
ogy; Asian origin; none; and other.
Reasons for pegfilgrastim usage were selected by phy-
sicians during the observation period from a drop-down 
list. Up to three reasons were selected in order of impor-
tance from the following list: planned chemotherapy 
with high risk of FN; age (≥ 65 years); advanced disease; 
prior FN; female; cardiovascular, kidney, or liver disease; 
poor performance status; poor nutritional status; anae-
mia; and other.
The category of pegfilgrastim use was derived program-
matically as follows:
 • PP: pegfilgrastim initiated within days 1–7 of che-
motherapy cycle 1, before neutropenia or FN had 
occurred, and G-CSF (either pegfilgrastim or other 
G-CSF) continued during each subsequent cycle.
 • SP: as above, but with pegfilgrastim initiated in cycle 2 
or later and irrespective of a neutropenic event.
 • Other: administration of pegfilgrastim that did not 
meet the conditions of PP or SP.
A patient was considered to have received chemotherapy 
that was:
 • Full dose: if they received ≤ 10 % dose reduction from 
the planned amount of any myelotoxic drug in any 
cycle
 • On schedule: if there was ≤ 3 days dose delay from the 
planned date in any cycle
 • Full dose on schedule: if both the above criteria were met
RDI was defined as the delivered dose intensity, expressed 
as a percentage of the prescribed dose intensity. The RDI 
of a multidrug regimen was the average of the RDIs for 
each of the individual drugs for each regimen. If a patient 
received more than one regimen, the RDI was averaged 
among all regimens, and sequential regimens were con-
sidered as one multicomponent regimen.
Statistical analysis
Primary and secondary outcomes were assessed using 
the full analysis set (FAS), which consisted of all patients 
who met the eligibility criteria and started a cycle of che-
motherapy. All statistical analyses were descriptive in 
nature. For continuous variables, descriptive statistics 
including the mean and standard deviation (SD) were 
reported. For categorical variables, the number and per-
low-up, or withdrew informed consent, whichever was 
sooner). Geographically representative centres across 
CEE and Austria were selected for patient recruitment, 
and sample size was calculated to ensure that the pro-
portion of patients with FN could be estimated with suf-
ficient precision within most subgroups. Approval of the 
various ethics committees was obtained according to the 
local laws and regulations of participating countries.
Patients
Adult patients with EBC, diffuse large B-cell lymphoma 
(DLBCL), lung, gastric, or ovarian cancer, who were 
planned to receive more than four cycles of chemother-
apy, had received pegfilgrastim according to the sum-
mary of product characteristics (SmPC) prior to initiation 
of the study, and who had an investigator-assessed over-
all risk of FN ≥ 20 % were eligible. Patients who were 
scheduled to receive dose-dense chemotherapy (such 
as CHOP-14), continuous single-agent chemotherapy, or 
weekly chemotherapy were excluded.
Outcomes
The primary outcome measure was the incidence of FN 
in any cycle, defined as grade III or IV neutropenia with 
concurrent temperature ≥ 38 °C.
Secondary outcome measures included the propor-
tion and characteristics of patients receiving pegfil-
grastim PP and SP, presence of FN risk factors, most 
frequently selected factors contributing to the decision 
to use pegfilgrastim, proportion of subjects receiving full 
dose on schedule, proportion of breast cancer patients 
achieving ≥ 85 % RDI and of lymphoma patients achiev-
ing ≥ 90 % RDI, incidence of FN in the first cycle, inci-
dence of hospitalisations associated with FN, incidence 
of IV anti-infective use associated with neutropenia, and 
safety profile of pegfilgrastim.
Data collection and definitions
Patients were observed and data were collected from the 
beginning of the first chemotherapy cycle up to a maxi-
mum of eight cycles. If patients received pegfilgrastim 
after cycle 1 (SP), then data from prior cycles were col-
lected retrospectively for those cycles before receiving 
pegfilgrastim. The last registered values before the start 
of treatment with pegfilgrastim were treated as baseline 
data. Safety-related events were collected, including 
adverse drug reactions (ADR) and serious adverse drug 
reactions (SADR) considered by the investigator as pos-
sibly related to pegfilgrastim.
Overall FN risk was assessed by physicians at baseline 
based on the myelotoxic potential of the chemotherapy 
regimen or the combination of the chemotherapy regi-
men and patient-related risk factors. Patient risk factors 
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The proportion of patients who received chemother-
apy with FN risk ≥ 20 % in cycle 1 was approximately 90 % 
for gastric cancer, 80 % for breast and lymphoma, and 
50 % for ovarian and lung cancer. Most of the remain-
ing patients in each tumour type received chemotherapy 
with an FN risk of 10–19 %, with very few receiving low-
risk chemotherapy or who were not assessed. Patient FN 
risk factors at baseline are shown in Table  2. The most 
frequently cited FN risk factors were female gender, 
advanced disease/metastasis, BSA < 2  m2, high planned 
dose intensity (≥ 80 %), age ≥ 65 years, and haemoglo-
bin < 12  g/dl. Baseline risk factors were more common 
in patients given pegfilgrastim as PP than those given 
SP, particularly advanced disease, high planned dose 
intensity, BSA < 2 m2, and cardiovascular comorbidities. 
SP patients were more likely to have had prior FN and 
low baseline ANC (Table 2), but since baseline data were 
defined as those taken immediately before pegfilgrastim 
initiation, in SP patients these risk factors would have 
been recorded after receipt of at least one chemotherapy 
cycle in the current course.
Incidence of febrile neutropenia
The incidence of FN in any cycle was 5 %, affecting 
51 patients (Table  3). FN incidence was 3 % (n = 28) in 
patients receiving pegfilgrastim as PP and 13 % (n = 19) 
in patients receiving pegfilgrastim as SP. Overall, FN 
occurred most commonly in cycle 1 (26 of 51 patients 
centage of participants in each category were reported, 
along with 95 % two-sided confidence intervals (95 % CI), 
calculated using Wilson’s formula, where appropriate.
Results
Study population
Patients were enrolled from 113 centres between August 
2010 and July 2013. The FAS included data from 1072 
patients from 111 centres in Austria (217 patients), Czech 
Republic (180), Poland (475), Romania (89), Slovakia 
(38), Slovenia (32), Hungary (24), and Bulgaria (17).
Patient and treatment characteristics are shown in 
Table  1. The population was generally young with good 
performance status. Breast cancer was the most common 
tumour type, accounting for 50 % of patients, followed by 
lymphoma (24 %), and lung (12 %), ovarian (11 %), and 
gastric cancer (4 %). Breast cancer patients tended to be 
younger and with fewer comorbidities, whereas lym-
phoma and lung cancer patients tended to be older and 
with more health-related complications. Overall, most 
patients had early stage cancer; however, most gastric and 
lung cancer patients had stage IV disease.
In this patient population, selected for having received 
pegfilgrastim, the majority (82 %) received pegfilgrastim 
as PP, with SP and other reasons accounting for 13 and 
5 %, respectively, and 91 % overall completed pegfilgras-
tim treatment as planned.
Table 1 Patient and treatment characteristics
Breast (N = 536) Lymphoma (N = 258) Gastric (N = 38) Ovarian (N = 113) Lung (N = 127) Total (N = 1072)
Age, median (range) 56 (25–82) 63 (23–91) 60 (39–74) 63 (38–84) 65 (30–84) 60 (23–91)
Female (%) 99 47 34 100 38 77
Body surface area, mean, m2 1.76 1.85 1.77 1.75 1.83 1.79
ECOG PS (%)
0–1 98 76 87 89 77 89
> 1 2 24 13 11 23 11
Cancer stage (%)
I–III 96 62 16 34 32 71
IV 0 38 68 28 59 22
Unknown 4 0 16 38 9 8
Prior incidence of FN 2 4 13 8 8 4
FN risk of chemotherapya (%)
< 10 1 1 3 4 2 2
10–19 16 20 8 43 46 23
≥ 20 78 79 89 50 52 73
Not assessed 4 0 0 3 0 2
Pegfilgrastim use (%)
Primary prophylaxis 83 87 76 81 66 82
Secondary prophylaxis 15 7 13 13 17 13
Other 1 6 11 5 17 5
ECOG PS Eastern Co-operative Oncology Group Performance Status, FN febrile neutropenia
aInvestigator assessed at cycle 1
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with FN, 51 %). In the SP group, a large majority of FN 
events occurred before pegfilgrastim was given, with 
79 % of cases (15 of 19 SP patients with FN) occurring in 
the first cycle of chemotherapy. In total, 32 patients (28 
PP and 4 SP patients, 3 %) suffered from FN while receiv-
ing pegfilgrastim prophylaxis. FN occurred in all cat-
egories of chemotherapy FN risk and was similar across 
cancer types, ranging from 3 % in breast cancer to 7 % in 
lymphoma patients.
Reasons for using pegfilgrastim
The three most frequently chosen factors contribut-
ing to the decision to use pegfilgrastim were planned 
chemotherapy with high risk of FN, female gender, and 
advanced disease, which applied to 81, 61, and 39 % of 
patients, respectively, overall (Fig. 1). The top three rea-
sons were the same irrespective of whether pegfilgrastim 
was given as PP or SP; however, prior FN and “other” rea-
sons were selected more often when pegfilgrastim was 
given as SP (13 and 28 % of patients, respectively), than 
when it was given as PP (3 and 14 %).
Chemotherapy delivery
Overall, 40 % of patients received > 90 % of their planned 
chemotherapy dose within 3 days of the planned sched-
ule (“full dose on schedule”; Table  4). The proportion 
of patients achieving full dose on schedule was highest 
for breast and ovarian cancer (52 and 50 %, respectively) 
and lowest for lymphoma (19 %). Forty-two per cent of 
PP patients and 32 % of SP patients received full dose 
Table 2 Patient risk factors for febrile neutropenia at base-
line






Age (≥ 65 years) 235 (22) 192 (22) 32 (23)
Advanced disease/metastases 369 (34) 309 (35) 40 (28)
Planned antibiotic prophylaxis 25 (2) 22 (3) 1 (1)
Prior FN 53 (5) 28 (3) 24 (17)
Female 727 (68) 624 (71) 86 (61)
Hb < 12 g/dl 212 (20) 172 (20) 30 (21)
Cardiovascular disease 142 (13) 130 (15) 6 (4)
Kidney disease 25 (2) 24 (3) 1 (1)
Elevated liver enzymes 31 (3) 25 (3) 4 (3)
High dose intensity planned 
(≥ 80 %)
236 (22) 212 (24) 18 (13)
Bad general condition/poor 
nutritional status
143 (13) 119 (14) 14 (10)
One or more comorbidities 63 (6) 54 (6) 7 (5)
BSA < 2 m2 318 (30) 285 (33) 25 (18)
ANC < 1.5 × 109/l before treat-
ment
35 (3) 17 (2) 14 (10)
Albumin ≤ 3.5 g/dl 33 (3) 32 (4) 1 (1)
Lymphoma histology 149 (14) 131 (15) 13 (9)
Asian origin 2 (0.2) 2 (0.2) 0 (0.0)
Other 67 (6) 37 (4) 25 (18)
Missing 35 (3) 18 (2) 0 (0)
The last registered values before the start of treatment with pegfilgrastim 
were treated as baseline data
BSA body surface area, ANC absolute neutrophil count, FN febrile neutro-
penia
Table 3 Incidence of febrile neutropenia
Category Any cycle First cycle
N Incidence of febrile neutropenia N Incidence of febrile neutropenia
n % (95 % CI) n % (95 % CI)
All patients 1072 51 5 (4, 6) 1072 26 2 (2, 4)
Pegfilgrastim primary prophylaxis 875 28 3 (2, 5) 875 9 1 (1, 2)
Pegfilgrastim secondary prophylaxis 142 19 13 (9, 20) 142 15 11 (7, 17)
FN risk of chemotherapya (%)
< 10 33 2 6 (2, 20) 18 0 0 (0, 18)
10–19 288 16 6 (3, 9) 249 8 3 (2, 6)
≥ 20 787 33 4 (3, 6) 779 18 2 (1, 4)
Not assessed 28 1 4 (1, 18) 26 0 0 (0, 13)
Cancer type
Breast 536 18 3 (2, 5) 536 10 2 (1, 3)
Lymphoma 258 19 7 (5, 11) 258 7 3 (1, 5)
Gastric 38 2 5 (2, 17) 38 1 3 (1, 13)
Ovarian 113 4 4 (1, 9) 113 4 4 (1, 9)
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Anti-infective treatment due to neutropenia was pro-
vided to 86 patients (8 %) overall. Anti-infective use var-
ied with tumour type, being more frequent for lymphoma 
(23 %) and infrequent for the other tumour types: ovarian 
(2 %); breast (3 %); gastric (3 %); and lung (6 %).
Safety
ADRs considered possibly related to pegfilgrastim were 
reported in 29 patients (3 %; 19 with breast cancer, 4 with 
lymphoma, 3 with gastric cancer, 2 with ovarian cancer, 
and 1 with lung cancer). The most common ADR was 
bone pain, which was experienced by 16 patients (1 %). 
One patient (0.1 %) with breast cancer experienced two 
SADRs considered possibly related to pegfilgrastim that 
occurred simultaneously (chest pain and back pain), 
and one lymphoma patient experienced an SADR of 
leucocytosis.
Discussion
In this patient population, which was considered to be 
at high FN risk and provided with pegfilgrastim support, 
the incidence of FN was relatively low. The FN rates of 
incidence for the two most common tumour types in this 
study, breast cancer and lymphoma (3 and 7 %, respec-
tively), were lower than those reported in observational 
studies in which pegfilgrastim was not an eligibility cri-
chemotherapy on schedule; the proportion of patients 
achieving full chemotherapy delivery tended to be higher 
when pegfilgrastim was given as PP for all tumour types 
except lung cancer. The proportion of patients receiv-
ing a prespecified RDI was calculated for breast cancer 
and lymphoma patients: 81 % of breast cancer patients 
(435/536) achieved RDI ≥ 85 % and 50 % of lymphoma 
patients (128/258) achieved RDI ≥ 90 %.
The proportion of patients with chemotherapy dose 
reduction ≥ 10 % varied widely according to tumour type, 
with the highest proportion occurring in lymphoma (78 %) 
and lowest in breast cancer (25 %); overall, the propor-
tion was 43 %. Compared with dose reductions, there was 
less variability between tumour types for the proportion 
of patients experiencing a dose delay by ≥ 3 days, which 
occurred in 41 % of patients overall and was highest for 
lung cancer (51 %) and lowest in breast cancer (33 %).
Technical issues were the most frequently listed rea-
son for both dose reductions (19 % of reduced cycles) and 
dose delays (34 % of delayed cycles). FN was infrequently 
cited as a reason for dose reduction (3 cycles, 0.1 %) or 
delay (6 cycles, 0.5 %). Neutropenia was cited as a reason 
for dose reductions in 32 cycles, 2 %, although more fre-
quently cited as a reason for dose delays (66 cycles, 6 %).
Incidence of hospitalisations associated with 
neutropenia and FN
Overall, 35 patients (3 %) were hospitalised due to FN, 
which accounted for one third of all hospitalisations. 
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81 Fig. 1 Most frequently se-
lected factors contributing to 
the decision to use pegfil-
grastim. Cumulative percent-
age frequencies are shown 
and represent the proportion 
of patients for whom each 
reason was selected as either 




1 3244  Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP)
cycle [40], and FN rates are lower in patients randomised 
to receive pegfilgrastim as PP rather than as SP or reac-
tively following a neutropenic event [13, 14]. Although 
not restricted at a national reimbursement level, local 
protocol in Romania requires a dossier to be submitted 
and approved before pegfilgrastim can be prescribed 
(personal communication, A. Macovei). Clearly, delays 
caused by this administrative process have the potential 
to endanger patient outcomes.
The baseline characteristics of the patients in this 
study were as expected for a younger, healthier popu-
lation, given chemotherapy treatment with curative 
intent that needs pegfilgrastim support. Other published 
observational studies concur with tumour-type pat-
terns reported here, for example, breast cancer patients 
tended to be younger and healthier than other cancer 
types [5, 27] and gastric cancer patients tended to have 
more advanced stage disease [29].
Most patients (98 %) received chemotherapy with a 
high, or at least intermediate, risk of FN, which indicated 
good guideline adherence, insomuch as pegfilgrastim 
was not being inappropriately given to patients at low 
risk of FN. However, despite almost 90 % of patients with 
gastric cancer receiving chemotherapy with ≥ 20 % FN 
risk, only 76 % received pegfilgrastim as PP.
The majority of patients received pegfilgrastim as 
PP, which is consistent with other studies and the sug-
gestion that SP is more commonly provided by a daily 
G-CSF [27, 29, 32]. Lung cancer patients had the lowest 
proportion of pegfilgrastim PP and highest proportion of 
“other” pegfilgrastim use; they also tended to be older, 
less healthy, and have more advanced stage disease. Per-
haps in this setting it was deemed more appropriate to 
delay chemotherapy, and indeed, dose delays were high-
est in this tumour type. Once pegfilgrastim prophylaxis 
was initiated, most patients continued to receive it in 
subsequent cycles. The low proportion of discontinua-
tion in this study (9 %) is similar to that reported from a 
study of US claims data, including adults diagnosed with 
non-Hodgkin lymphoma (NHL) or breast cancer [28] and 
is an important statistic, since early discontinuation of 
pegfilgrastim prophylaxis after the first two chemother-
apy cycles has been shown to lead to unacceptably high 
incidence of FN [41].
terion and G-CSF use was lower (4–17 %, and 10–22 %, 
respectively) [5, 27, 30, 32, 33, 38]. However, the overall 
rate of FN incidence in this study (5 %) was similar to that 
previously reported in pegfilgrastim-treated patients in 
Austrian clinical practice (6 %) [33]. This magnitude of FN 
risk reduction appears slightly higher than expected from 
clinical studies, which has been shown in meta-analyses 
to be reduced by 70 % for pegfilgrastim PP versus placebo 
[19]. In general, these results show that the efficacy of 
pegfilgrastim observed in clinical studies is maintained 
in clinical practice across a broad population of tumour 
types and regimens, although since patient outcome is 
influenced by many other factors, such as the planned 
and received dose intensity, etc., it is difficult to draw 
further conclusions from a comparison of these results.
As reported in other observational studies, the PP and 
SP groups in this study were unbalanced with respect to 
risk factors and probably treatment intent [24, 27, 29, 32, 
33], and comparisons between these groups should be 
interpreted with caution. Patients may be selected for 
PP over SP because they are considered to be at greater 
risk of experiencing FN (due to the presence of patient 
risk factors and/or receipt of high-risk chemotherapy) 
or because maintaining chemotherapy dose intensity is 
considered important for survival outcomes. Neverthe-
less, the incidence of FN was lower when pegfilgrastim 
was given as PP than when it was provided as SP. In fact, 
the data suggest that FN may have often been a trigger 
for providing pegfilgrastim SP, which implies that better 
risk assessment—and response to risk assessment—may 
have improved outcomes for these patients.
In observational studies of real clinical practice, such 
as this one, results are not only influenced by the clinical 
judgement of physicians but also regulations surround-
ing reimbursement. Out of the eight countries involved, 
only Hungary, representing 24 patients (2 % overall), had 
a national-level reimbursement restriction for pegfil-
grastim, which restricted use to SP following a previous 
chemotherapy cycle with certain specified neutropenic 
events [39]. This reimbursement condition restricts Hun-
garian practitioners from following international guide-
lines [18, 25, 26]. Furthermore, restricting pegfilgrastim 
support to SP is particularly significant since FN has been 
shown to occur most frequently in the first chemotherapy 
Table 4 Patients achieving full dose chemotherapy on schedule
Category Overall Primary prophylaxis Secondary prophylaxis
N Full dose on schedule N Full dose on schedule N Full dose on schedule
n % (95 % CI) n % (95 % CI) n % (95 % CI)
All patients 1072 428 40 (37, 43) 875 369 42 (39, 46) 142 46 32 (25, 41)
Cancer type
Breast 536 280 52 (48, 56) 445 247 56 (51, 60) 83 32 39 (29, 49)
Lymphoma 258 48 19 (14, 24) 225 45 20 (15, 26) 18 0 0 (0, 18)
Gastric 38 10 26 (15, 42) 29 8 28 (15, 46) 5 0 0 (0, 43)
Ovarian 113 57 50 (41, 60) 92 50 54 (44, 64) 15 5 33 (10, 70)
Lung 127 33 26 (19, 34) 84 19 23 (15, 33) 21 9 43 (25, 64)
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one third of all hospitalisations in the study and affecting 
35 patients. It is therefore important to ensure that high-
risk patients are identified and treated according to inter-
national guidelines to prevent FN where possible.
The study was not designed to examine survival out-
comes; however, appropriate G-CSF support can reduce 
the risk of mortality during treatment and may improve 
long-term survival outcomes. The administration of 
G-CSF is associated with improved survival, and two 
closely interlinked mechanisms can be identified: directly 
by reducing the incidence of potentially life-threatening 
FN [42] and indirectly by improving chemotherapy RDI 
and thus anti-tumour efficacy [43–45]. The risk of FN is 
usually highest in cycle 1 of chemotherapy. After occur-
rence of an FN event, chemotherapy dose is reduced 
and/or the administration of a new cycle delayed, both 
of which leads to reductions in RDI. However, it has been 
shown that chemotherapy drug concentration for many 
chemotherapeutic agents correlates directly with the rate 
of tumour cell eradication [6].
As with all observational studies, a lack of control for 
bias and the influence of confounding factors limit the 
ability to draw conclusions from comparisons of patient 
groups, particularly the PP and SP groups, within this 
study. Many factors influence recruitment into observa-
tional studies, and so recruitment in relation to national 
populations cannot be expected. In this study, recruit-
ment across the participating countries was indeed 
uneven, with Hungary, Romania, and Bulgaria being 
particularly underrepresented in relation to the national 
populations. The reasons why pegfilgrastim PP was not 
given to patients at ≥ 20 % risk of FN, and whether local 
protocols may have restricted use of pegfilgrastim, were 
not asked for in the study. The definition of FN used was 
less stringent than other prospective studies and the 
EORTC guidelines [18] (published after study start) as 
it included grade III neutropenia with fever. However, 
events such as FN are likely to be less well documented 
in observational studies than clinical studies and there-
fore underreporting may have contributed to the low FN 
rates observed. The observed reductions in chemother-
apy dose intensity, especially in lymphoma patients, may 
have been used to decrease the FN risk, albeit with pos-
sible consequences for survival outcomes. These ques-
tions would be important topics for future studies.
Conclusions
In patients with an overall FN risk of ≥ 20 % and who had 
received pegfilgrastim, most patients received pegfilgras-
tim as PP, and incidence of FN was low (5 %). However, 
60 % of the patients did not receive full chemotherapy 
dose on schedule, and chemotherapy delivery was lowest 
in lymphoma patients. The most important reasons for 
pegfilgrastim use were consistent with the investigators’ 
risk assessment and international guidelines; however, 
18 % of patients did not receive pegfilgrastim PP, despite 
being considered to be at high risk of FN and harbouring 
The three most frequently chosen reasons for pegfil-
grastim use (planned chemotherapy with high risk of 
FN, female gender, and advanced disease) were also the 
most frequently occurring FN risk factors that could be 
selected, indicating good alignment of the reasons for 
prophylaxis with actual FN risk.
Many of the most common baseline patient risk fac-
tors present in patients receiving PP were also commonly 
observed in the patients who received SP, for example, 
female gender, advanced disease/metastasis, age ≥ 65 
years, and haemoglobin < 12 g/dl, raising the question of 
why these patients did not receive PP. Although current 
guidelines provide a list of individual patient risk factors 
that contribute to overall FN risk [18, 25, 26], a validated 
model that quantifies the relative contribution of specific 
risk factors is not currently available.
The outcome of achieving full dose on schedule, as 
defined in this study, was achieved by a lower proportion 
of breast cancer and lymphoma patients than the more 
commonly reported measure of chemotherapy delivery 
based on RDI, making it a more stringent target, but one 
that we consider to be clinically relevant. The propor-
tion of breast cancer patients who achieved RDI ≥ 85 % in 
this study (81 %) is higher than that observed in the pre-
vious study in CEE (56 %) in which G-CSF was given to 
approximately half the patients [30], although similar to 
that reported in observational studies from other regions 
[4, 5, 27]. Only 50 % of lymphoma patients achieved 
RDI ≥ 90 % in this study. Similar to breast cancer, this 
again appears higher than observed in the previous CEE 
study (36 % of patients with RDI ≥ 85 %) but is within the 
range reported in other observational studies [5, 30–32]. 
The difference in the proportion of patients achieving 
full dose on schedule for breast cancer (52 %) and lym-
phoma (19 %) is unclear, particularly considering the 
importance of chemotherapy delivery in relationship to 
long-term outcomes is well established in both tumour 
types but may be related to the very aggressive therapy 
usually given to NHL patients. Bearing in mind the cave-
ats of comparing PP and SP groups, a higher proportion 
of patients who received pegfilgrastim as PP than as SP 
received chemotherapy on schedule. High planned dose 
intensity plays a decisive role in the decision to adminis-
ter PP, and it is therefore interesting that fewer patients 
in the SP group had planned high dose intensity, thus 
making dose delays more acceptable for this group. Also, 
important differences between countries were observed 
in their strategies to manage the risk of FN. The propor-
tion of patients with chemotherapy-related FN risk ≥ 20 % 
receiving pegfilgrastim PP was 88 % overall (Austria 91, 
Czech Republic 78, Poland 93.5, and Romania 75 %). In 
contrast, the proportions of patients receiving full che-
motherapy dose on schedule were 40 % overall (Austria 
37, Czech Republic 42, Poland 49, and Romania 18 %), 
suggesting that reductions in chemotherapy dose inten-
sity may have been used to decrease the FN risk, albeit 
with possible consequences for survival outcomes.
Despite FN occurring in a relatively low proportion of 
patients, the impact was nevertheless significant, causing 
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commonly recognised FN risk factors. In those patients 
who received pegfilgrastim as SP, most FN occurred 
before pegfilgrastim support was provided; a better risk 
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these patients may lead to reduced incidence of FN.
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